Hebei Medical University Fourth Hospital

This study tests two different chemotherapy drug combinations in people with advanced triple-negative breast cancer, a fast-growing type. About 414 participants will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus capecitabine. The goal is to see which combi…

This study is testing a treatment for early-stage breast cancer that combines breast-conserving surgery with a single dose of radiation given during the operation. It involves 620 women aged 55 or older with small, HER2-negative tumors. The goal is to see if this approach lowers …

This study looks at whether a drug called trilaciclib can protect the bone marrow in people with solid tumors receiving chemotherapy. The goal is to reduce severe drops in blood cells, which can be dangerous and delay treatment. About 100 adults will take part, first by reviewing…

This study tests two different chemotherapy combinations (nab-paclitaxel plus carboplatin vs. nab-paclitaxel plus epirubicin) given before surgery to shrink tumors in people with triple-negative breast cancer. The goal is to see which combo works better at eliminating cancer cell…

This study tests whether adding a drug called entinostat to a standard treatment (dalpiciclib plus letrozole) works better at shrinking tumors before surgery in people with a common type of early breast cancer (HR+/HER2-). About 60 women will be randomly assigned to one of two tr…

This study tests a combination of four drugs (iparomlimab, tuvonralimab, apatinib, and irinotecan) in 39 adults with advanced AFP-producing stomach or gastroesophageal junction cancer that worsened after initial PD-1 inhibitor plus chemotherapy. The goal is to see if this new mix…

This study tests whether adding bevacizumab to standard chemotherapy before surgery can improve outcomes for people with early or locally advanced HER2-negative breast cancer. About 75 adults will receive the combination, and researchers will measure how many achieve a complete r…

This study tests whether the drug adebrelizumab can help prevent esophageal cancer from returning after surgery. About 142 adults who had their cancer completely removed will receive either adebrelizumab or a placebo. The goal is to see if the drug improves how long people stay c…

This study looks at how well and how safely the drug dalpiciclib works for people with a type of advanced breast cancer called HR-positive. Researchers will follow 420 patients who are already taking or about to take dalpiciclib as part of their normal care. The goal is to see ho…

This study compares a new targeted therapy (dalpiciclib plus an aromatase inhibitor) against standard chemotherapy for postmenopausal women with a specific type of early breast cancer (ER-positive, HER2-negative, low growth rate). The goal is to see if the new combo works just as…

This study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy can shrink tumors and slow disease in people with advanced esophageal cancer that has come back or spread. About 25 adults whose cancer cannot be removed by surger…

This study looks at whether a medicine called mecapegfilgrastim can help prevent neutropenia (dangerously low white blood cells) in cancer patients after chemotherapy, radiation, or immunotherapy. About 200 adults with solid tumors will receive the injection to see if it reduces …

This study aims to create an early warning system that predicts organ damage in cancer patients receiving immunotherapy. Researchers will analyze genetic, protein, and other biological data from 2,000 participants to identify warning signs of side effects. The goal is to help doc…